Synthetic Triterpenoids Nrf2 Activation Renal Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for renal/kidney disease, insulin resistance, diabetes, endothelial dysfunction, and cardiovascular disease are inadequate in halting or reversing the progression of these conditions, with existing therapies failing to effectively improve compromised renal function and addressing underlying oxidative stress and inflammation.
Innovation Solution
Administration of synthetic triterpenoids, such as CDDO-Me and related compounds, which activate the Keap1/Nrf2/ARE pathway to induce antioxidant and anti-inflammatory proteins, reducing serum creatinine levels and improving glomerular filtration rate by suppressing NF-κB and STAT3 activities and enhancing Phase 2 responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for renal/kidney disease, diabetes, and cardiovascular disease, then current standard of care is maintained, but progression of disease is not halted or reversed and renal function is not improved
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of triterpenoid compounds (changing molecular parameters) to enhance their biological activity. Specifically, the synthesis of CDDO and its derivatives involves altering functional groups and molecular configurations to improve potency in activating Nrf2 and suppressing inflammatory pathways, thereby resolving the contradiction between maintaining standard care reliability and achieving improved renal function outcomes
Solution Approach 2:
The patent employs composite materials by combining multiple pharmacological mechanisms into a single compound class. The synthetic triterpenoids simultaneously activate antioxidant pathways (Nrf2/ARE), suppress inflammatory mediators (NF-κB, STAT3), and modulate multiple disease processes, creating a multi-functional therapeutic agent that addresses both disease progression control and renal function improvement
2Reliability
If naturally-occurring triterpenoids like ursolic and oleanolic acids are used, then anti-inflammatory and anti-carcinogenic activity is provided, but biological activity is relatively weak
Solution Approach 1:
The patent directly applies parameter changes by systematically modifying the chemical parameters of naturally-occurring triterpenoids. The synthesis of CDDO involves adding functional groups (cyano group at C-2, dioxo groups at C-3 and C-12) to the oleanolic acid skeleton, which dramatically enhances the compound's ability to activate Nrf2 and suppress inflammatory pathways, thereby resolving the contradiction between maintaining anti-inflammatory reliability and achieving higher biological potency
Solution Approach 2:
The patent applies local quality by introducing specific functional groups at particular positions on the triterpenoid molecular structure. The cyano group at C-2 and the dioxo groups at C-3 and C-12 are strategically placed to enhance interaction with nuclear receptors and enzymatic targets, creating localized regions of high chemical reactivity and binding affinity that amplify the overall biological activity while preserving the core anti-inflammatory mechanism
3Productivity
If no new treatment mechanisms are developed, then current treatment limitations are maintained, but significant advance in treating renal failure cannot be achieved
Solution Approach 1:
The patent employs the intermediary mechanism by utilizing the Nrf2 protein as a molecular mediator. The synthetic triterpenoids act as upstream activators that trigger the Nrf2/ARE signaling pathway, which in turn activates a cascade of downstream antioxidant and anti-inflammatory genes. This intermediary approach allows a single compound to regulate multiple protective pathways simultaneously, achieving both improved renal function and reliable treatment effectiveness through coordinated molecular signaling
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of synthetic triterpenoids like CDDO-Me effectively reduces serum creatinine levels, improves renal function, and alleviates endothelial dysfunction, offering a significant advancement in treating and preventing renal/kidney disease, insulin resistance, diabetes, and cardiovascular disease by targeting oxidative stress and inflammation.
Implementation Method 1
RTA 402 has also been reported to activate the Keap1/Nrf2/ARE signaling pathway resulting in the production of several anti-inflammatory and antioxidant proteins
Implementation Method 2
enhancing Phase 2 responses
Implementation Method 3
suppressing NF-κB and STAT3 activities
Implementation Method 4
suppressing NF-κB and STAT3 activities
Data Source
Figure 1a~1d
Figure 2a~2c
Figure 3a~3d
AI summary
The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.